Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Insulet

Option Trading: Insulet Butterfly Taps Into Stock's Leadership, Potential Rally

Health care services and health-related stocks continue to show strength in the market.

Investors Business Daily

Insulet Joins S&P 500 And Gets Ready To Pump Up New Breakout With 56% Growth

After Insulet jumped on news it was joining the S&P 500, PODD stock is wound up for a breakout with earnings due.

Investors Business Daily

5 S&P 500 Stocks Near Buy Points As Recession Fears Rise

Medical stocks are holding up amid economic and market uncertainty.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

IBD Screen Of The Day: AMD Surges Past Buy Point, Chipotle Boast Rising Profit Estimates

AMD stock surged past a new buy point in today's stock market action, while Chipotle boasts rising profit estimates.

Investors Business Daily

Dow Jones Rises After Cool Inflation Report, Weak Retail Sales; Tesla Extends Gains

The Dow Jones Industrial Average rose Wednesday on a cool inflation report and weak retail sales. Tesla stock raced higher, looking to add to Tuesday's surge.

Investors Business Daily

Dow Jones Drops After Weak Manufacturing Data; Goldman Sachs Slides On Earnings Miss

The Dow Jones dropped Tuesday ahead of more key inflation data due out Wednesday. Goldman Sachs fell on an earnings miss.

Investors Business Daily

Dow Jones Futures Fall After Market Rally Clears Resistance; Tesla China Sales Get Bump

Futures fell after the market rally cleared resistance last week. Time to act, carefully. Tesla China sales rose post-price cuts.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market Rally

Dow giant UnitedHealth is among 5 stocks holding key support while the overall market weakens.

Investors Business Daily

Dow Jones Futures Rise After Stock Market Rally's Ugly Week; Tesla Bounces On Musk Twitter Poll

The market rally started strong, but sold off hard in a big outside week. Leading stocks tumbled. Tesla plunged, but is trying to bounce. Here's what to do.

Investors Business Daily

IBD Stock Of The Day: Why An Analyst Says The Rich Valuation For Insulet Is Justified

Diabetes devices maker Insulet is the IBD Stock Of The Day as PODD stock hovers in a buy zone near its 21-day moving average.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022

Upgrades

Benzinga

Neurocrine Leads 5 Stocks To Watch In Sickly Market

Neurocrine Biosciences leads five medical stocks near key support levels as the health care sector shows resilience in a sickly market.

Investors Business Daily

Dow Jones Futures: Market Expects This From Fed Chief Powell; 5 Stocks In Buy Zones

Several stocks flashed buy signals as the market rallied heading into Fed chief Powell's speech. Here's what to expect.

Investors Business Daily

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures Fall As Market Retreat Gains Steam; Elon Musk Makes This FSD Move

Futures fell sharply as the market rally pulls back. Elon Musk will hike Tesla FSD prices. Warren Buffett stock Occidental Petroleum surged Friday.

Investors Business Daily

IBD Stock Of The Day Insulet Edges Closer To A Breakout On This 'Game Changer'

Insulet is the IBD Stock Of The Day as excitement around the company's new insulin pump, Omnipod 5, drives PODD stock closer to a breakout.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022

Upgrades

Benzinga

5 Analysts Have This to Say About Insulet

Insulet (NASDAQ:PODD) has observed the following analyst ratings within the last quarter:

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

4 Analysts Have This to Say About Insulet

Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:

Investors Business Daily

Dexcom Pops After Insulet Buyout Rumor Shakes Up Diabetes Stocks

Dexcom stock popped Tuesday after the diabetes devices company refuted rumors that it's in active negotiations to acquire any company.

Benzinga

Looking Into Insulet's Return On Capital Employed

According to Benzinga Pro, during Q1, Insulet (NASDAQ:PODD) earned $27.80 million, a 4.79% increase from the preceding quarter. Insulet's sales decreased to $295.40 million, a 4.0% change since Q4.

Investors Business Daily

How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space

Dexcom stock yo-yoed Wednesday after a Tuesday dive on rumors it's in talks to acquire insulin pump-maker Insulet in a major diabetes deal.

Benzinga

Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg

Dexcom Inc (NYSE:DXCM) is reportedly in talks to acquire medical-device company Insulet Corporation (NASDAQ: PODD) to create a giant in diabetes devices, according to people with knowledge of the matter. According to Bloomberg, talks between the companies are ongoing, and an agreement could be reached in the coming weeks. Discussions could still be delayed or fall…

Benzinga

Expert Ratings for Insulet

Within the last quarter, Insulet (NASDAQ:PODD) has observed the following analyst ratings:

Benzinga

Insulet Q1 Earnings Beats Street View, Says Omnipod 5 Rollout Is 'Progressing Very Well'

Insulet Corporation (NASDAQ:PODD) posted Q1 profits of $27.8 million, or an EPS of $0.40, beating the consensus of $0.23. Q1 sales increased 17.1% Y/Y, or 19.3% in constant currency, to $295.4 million, exceeding the guidance range of 13% to 16% in constant currency and the consensus of $288.18 million. “We are off…

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.